Perspective Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
CATX$0.79-8.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Perspective Therapeutics, Inc. and Subsidiaries
Consolidated Statements of Cash Flows
(In thousands)
| Year ended December 31, · Six months ended December 31, · Year ended June 30, | |||||
|---|---|---|---|---|---|
| 2023 · 2022 · 2022 | |||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | |||||
| Net loss | $(46,508) | $(7,335) | $(7,272) | ||
| Adjustments to reconcile net loss to net cash used by operating activities: | |||||
| Lease expense | 75 | 2 | 4 | ||
| Depreciation expense | 946 | 138 | 248 | ||
| Write-off of inventory associated with discontinued product | 298 | - | - | ||
| Loss on disposal of property and equipment | 22 | 305 | - | ||
| Amortization of other assets | 40 | 21 | 41 | ||
| Accretion of asset retirement obligation | 35 | 17 | 32 | ||
| Equity in loss of affiliate | 17 | - | - | ||
| Accrued interest on short-term investments | - | (226) | - | ||
| Change in allowance for doubtful accounts | 624 | - | - | ||
| Change in estimate of asset retirement obligation | (15) | - | - | ||
| Loss recognized on classification as held for sale | 4,170 | - | - | ||
| Share-based compensation | 3,738 | 672 | 1,087 | ||
| Deferred income tax benefit | (2,651) | - | - | ||
| Changes in operating assets and liabilities: | |||||
| Accounts receivable, net | (426) | 245 | 405 | ||
| Inventory | 359 | (76) | (2,673) | ||
| Prepaid expenses and other current assets | (325) | (249) | 46 | ||
| Accounts payable and accrued expenses | 1,584 | 573 | 236 | ||
| Accrued protocol expense | 89 | 83 | 52 | ||
| Accrued radioactive waste disposal | (100) | 9 | 20 | ||
| Accrued payroll and related taxes | 1,274 | (297) | 70 | ||
| Accrued vacation | (159) | 32 | (6) | ||
| Net cash used by operating activities | (36,913) | (6,086) | (7,710) | ||
| CASH FLOWS FROM INVESTING ACTIVITIES: | |||||
| Additions to property and equipment | (1,072) | (151) | (266) | ||
| Additions to other assets | (18) | - | (18) | ||
| Additions to equity method investment | - | (150) | - | ||
| Proceeds from maturity of short-term investments | 22,764 | 12,538 | - | ||
| Purchases of short-term investments | - | (35,076) | - | ||
| Investment in note receivable | - | (6,000) | - | ||
| Net cash acquired in acquisition of Viewpoint | 2,699 | ||||
| Net cash provided by (used in) investing activities | 24,373 | (28,839) | (284) | ||
| CASH FLOWS FROM FINANCING ACTIVITIES: | |||||
| Repayment of notes payable | (68) | - | - | ||
| Proceeds from sales of common stock, pursuant to exercise of options | 554 | 28 | 56 | ||
| Proceeds from at the market offering | 364 | - | - | ||
| Issuance costs related to common stock issued in exchange for Viewpoint common stock | (65) | - | - | ||
| Net cash provided by financing activities | 785 | 28 | 56 | ||
| Net decrease in cash, cash equivalents and restricted cash | (11,755) | (34,897) | (7,938) | ||
| Cash, cash equivalents and restricted cash beginning of period | 21,175 | 56,072 | 64,010 | ||
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH END OF PERIOD | $9,420 | $21,175 | $56,072 | ||
| Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets: | |||||
| Cash and cash equivalents | $9,238 | $20,993 | $55,890 | ||
| Restricted cash | 182 | 182 | 182 | ||
| Total cash, cash equivalents and restricted cash | $9,420 | $21,175 | $56,072 | ||
| Supplemental disclosure of cash flow information: | |||||
| Interest paid | $84 | $ | - | $ | - |
| Noncash investing and financing activities: | |||||
| Fair value of Viewpoint assets acquired including goodwill | $82,628 | $ | - | $ | - |
| 136,545,075 shares of Perspective Therapeutics common stock issued in exchange for Viewpoint common stock | (54,618) | - | - | ||
| Assumption of Viewpoint stock options and warrants at fair value | (7,836) | - | - | ||
| Note receivable and accrued interest from Viewpoint forgiven | (6,171) | - | - | ||
| Viewpoint liabilities assumed including deferred tax liabilities established through accounting for business combinations (see Note 14) | 14,003 | - | - | ||
| Modification of operating lease liability and right of use asset | 557 | - | - | ||
| Operating lease liability and right of use asset for new lease | 811 | - | - | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.